AstraZeneca Pharma India Ltd will receive 260 million rupees from Sun Pharma as part of a strategic collaboration to market Sodium Zirconium Cyclosilicate (SZC) for hyperkalaemia treatment. AstraZeneca will sell the drug under the brand Lokelma, while Sun Pharma will market it as Gimliand, enhancing patient access nationwide.
Shraddha Prime Projects Ltd has announced the purchase of development rights in Borivali East, marking a major expansion in one of Mumbai’s most promising residential hubs. With an estimated GDV of 4 billion rupees, the project is strategically positioned near Nency Colony, offering excellent connectivity and access to essential amenities. This acquisition underscores the company’s commitment to creating modern, well-connected residential communities that cater to both homebuyers and investors.
Key Highlights
-
Notable updates include the project’s location near Nency Colony, offering direct access to Western Express Highway, Borivali Railway Station, and the upcoming Borivali Metro Station
-
Proximity to schools, hospitals, shopping malls, and temples, making it an attractive choice for families and professionals
-
Shraddha Prime Projects’ focus on quality housing solutions, with this development expected to consolidate its presence in Mumbai’s real estate sector
-
Strategic expansion into Borivali East aligns with the company’s vision of delivering modern living spaces in prime locations
Sources: Shraddha Park City official site, Shraddha Pratham Borivali East project page